CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities
Net income (loss)	$ (22,088)	$ (25,946)
Less: Net income from discontinued operations		14,313
Net loss from continuing operations	(22,088)	(40,259)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	625	980
Amortization and accretion income, net	(678)	2
Ampreloxetine interest accretion	550
Share-based compensation	7,021	14,545
Undistributed earnings from TRC, LLC		7
(Gain) loss on disposal of property and equipment	29	(218)
Interest payable on 2023 notes		1,869
Amortization of right-of-use assets	1,031	341
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	4,515	1,788
Prepaid clinical and development services	(13)	5,503
Other prepaid and current assets	1,401	2,436
Right-of-use lease assets	(109)
Other assets	1,270	1
Accounts payable	1,002	(1,619)
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(4,337)	(10,344)
Deferred revenue	(6)	(9)
Operating lease liabilities	(966)	(1,715)
Other long-term liabilities	(468)	8
Net cash used in operating activities - continuing operations	(11,221)	(26,684)
Net cash (used in) provided by operating activities - discontinued operations		615
Net cash used in operating activities	(11,221)	(26,069)
Investing activities
Purchases of property and equipment	(938)	(250)
Purchases of marketable securities	(134,533)	(18,174)
Maturities of marketable securities	29,500	48,499
Sale of short-term investments and marketable securities	62,715
Proceeds from the sale of property and equipment	210	1,849
Net cash provided by investing activities - continuing operations	(43,046)	31,924
Net cash provided by investing activities	(43,046)	31,924
Financing activities
Ordinary share repurchases	(55,353)
Repurchase of shares to satisfy tax withholding	(887)	(1,448)
Net cash (used in) provided by financing activities - continuing operations	(56,240)	(1,448)
Net cash (used in) provided by financing activities	(56,240)	(1,448)
Net increase in cash, cash equivalents, and restricted cash	(110,507)	4,407
Cash, cash equivalents, and restricted cash at beginning of period	299,008	90,796
Cash, cash equivalents, and restricted cash at end of period	188,501	95,203
Supplemental disclosure of cash flow information
Cash paid for interest		$ 4,613
Cash paid (received) for income taxes, net	7
Supplemental disclosure of non-cash investing and financing activities
Recognition of tenant improvement allowance assigned to sublease	$ 6,490